Study of Adebrelimab Combined With Thymalfasin and Chemotherapy for Neoadjuvant Treatment of Esophageal Cancer

What Was Tested

This registered phase 2 trial tested Thymosin Alpha-1.

This is a prospective, single-arm, multicenter clinical study conducted in China.

The study consists of a screening period (from the signing of informed consent by subjects to the first study drug administration, no more than 21 days), a treatment period (including neoadjuvant therapy and surgery), and a follow-up period (comprising safety follow-up and survival follow-up).

It had 1 arm (groups): Treatment Arm (Adebrelimab + Thymalfasin + Chemotherapy Neoadjuvant Regimen) (experimental).

All eligible patients receive neoadjuvant therapy for 2-3 cycles (3 weeks per cycle), followed by radical esophagectomy with lymph node dissection.

The registry classes the interventions as drug.

Who Took Part

Enrollment: 31 planned participants were the target.

It was open to people of any sex aged from 18 years up to 80 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Has signed the written informed consent form and voluntarily participates in this study;. Aged 18-80 years, male or female;. Histopathologically or cytologically confirmed esophageal squamous cell carcinoma;. Clinical stage: cT1b-cT2N+M0 or cT3-cT4a any N M0;. Expected to achieve R0 resection;.

The full record lists 16 inclusion and 18 exclusion criteria; among the exclusions: tumor invades adjacent organs of the esophageal lesion (major arteries or trachea);; uncontrolled pleural effusion, pericardial effusion or ascites requiring repeated drainage;; history of allergy to any component of monoclonal antibodies, adebrelimab, thymalfasin, paclitaxel, carboplatin or other platinum agents;.

How the Study Was Run

Design: single-group and open-label.

Being open-label, the Thymosin Alpha-1 study did not mask who received what.

Everyone received the same intervention, so there was no separate comparison group inside the trial.

It started in 2026-08-30 with completion listed for 2028-08-01.

It ran at 1 site in China.

Its stated primary purpose is treatment.

What Was Measured

Primary outcome: Pathologic Complete Response (pCR) Rate (time frame: 2 weeks after surgery).

It also tracked 6 secondary outcomes, for example R0 Resection Rate, Major Pathologic Response （MPR）Rate, Disease-Free Survival(DFS), Objective Response Rate(ORR）, Overall Survival(OS) and Incidence and Grade of Adverse Events and Serious Adverse Events [Safety and Tolerability].

What This Means in Plain Language

Put simply, this is a phase 2 trial of Thymosin Alpha-1 in 31 people.

Its size is small, so on its own it can only give an early look.

Its status is not yet recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Thymosin Alpha-1 compound page, all human trials.